

Sartorius Places 200 Million Euro Note Loan

Goettingen, December 15, 2016 – Sartorius, a leading international laboratory and pharmaceutical equipment provider, successfully placed a note loan with a volume of 200 million euros.

Arranged by Landesbank Baden-Württemberg and BNP Paribas, the note loan with maturity terms of 5, 7 and 10 years was subscribed by national and international financial institutions, primarily savings banks and credit unions. In view of the high demand by debt investors, the issue of the note loan was increased from 150 million euros to 200 million euros. The issue will be used for general corporate financing purposes and represent a further long-term component of the Group's funding structure.

"By issuing this note loan, we are securing attractive long-term conditions for the company in the currently low interest rate environment and are further broadening our Group financing," said Jörg Pfirrmann, CFO and member of the Executive Board of Sartorius AG.

Image File

https://www.sartorius.de/fileadmin/media/global/company/Pfirrmann_Sartorius.jpg

Jörg Pfirrmann, CFO and member of the Executive Board of Sartorius AG

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

A Profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.1 billion euros in 2015. More than 6,200 people work at the Group's approximately 50 manufacturing and sales sites, serving customers around the globe.

Contact

Petra Kirchhoff

Vice President of Corporate Communications and Investor Relations

+49 (0)551.308.1686

petra.kirchhoff@sartorius.com